The incidence, pathophysiology, provoking factors, and recommended treatments for several types of unusual thrombosis were summarized in a review article.
Andexanet alfa is the first anticoagulant reversal agent to receive global US FDA approval for patients with life-threatening or uncontrolled bleeding.
A dataset comprising 672 tumor specimens collected from 562 patients describes both genetic and functional information about the biology of AML.
Recent evidence links specific bacterial, viral infections, and vaccination to the development of APS, but these associations are not clear-cut.
Eculizumab has been used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.